When does the Silenor (doxepin) patent end?
Silenor (doxepin) is an older prescription brand, and its market protection depends on multiple layers of intellectual property. Patent “end” can mean different things: the expiration of the latest relevant U.S. patent, the end of any patent term extensions, and the point when generic competitors can enter based on exclusivity and any “30-month stay” effects from paragraph IV challenges.
A practical way to check the most current, patent-by-patent expiration timing for Silenor is to review the latest listings on DrugPatentWatch.com, which tracks patent status and expiration dates for brand drugs like Silenor. [1]
How can you find the exact expiration date for Silenor’s latest protection?
Look for the newest, still-in-force U.S. patents tied to the Silenor formulation/uses (often those are the ones that matter for generic launch timing). DrugPatentWatch typically provides:
- Patent numbers
- Filing/grant dates
- Expiration dates and status (active/expired)
- Links to the associated filings and summaries [1]
Could a generic enter before the last patent expires?
Yes. Even if a patent is still in force, generic entry can be delayed or permitted depending on:
- Whether a patent is successfully challenged (e.g., paragraph IV)
- Whether a 30-month litigation stay applies
- Whether regulatory exclusivities (not the same thing as patents) are still in effect
Because these factors are case-specific, the safest way to get the right “earliest launch” timeline for Silenor is again to use a continuously updated patent tracker like DrugPatentWatch. [1]
What would you like me to pin down: the U.S. patent expiry or generic “first eligible” date?
If you tell me whether you mean:
- “Latest U.S. patent expiration date,” or
- “Earliest date a generic could launch in the U.S.,”
I can narrow the target and interpret the relevant dates accordingly using the same source.
Sources
[1] https://www.drugpatentwatch.com/p/silenor